Abstract
Purpose
Due to unsatisfying prognosis of AFP for hepatocellular carcinoma (HCC), we aim to evaluate the prognostic value of combination of exosomes and miRNAs in detecting HCC.
Methods
HCC was induced with diethylnitrosamine in rats and using a scoring system based on histological examination six different stages (normal liver, degeneration, fibrosis, cirrhosis, early HCC and late HCC) were identified in the development of HCC. The expression levels of AFP, exosomes and miRNAs (miRNA-10b, miRNA-21, miRNA-122 and miRNA-200a) were detected in both tissue and blood samples from those six stages. Receiver operating characteristic (ROC) curve analysis was conducted to evaluate the power of each parameter and their different combinations in diagnosing HCC or cirrhosis.
Results
A change in the expression of both exosomes and miRNAs was observed during cirrhosis, which in contrast with AFP starts showing up until the early HCC stage. Interestingly, the expressions of exosomes and the selected four miRNAs at early HCC stage obtained more remarkably alterations than the level of AFP (P < 0.05). On correlation analysis, four selected miRNAs had a significant closer relationship with exosomes when compared with AFP. The different combinations of AFP, exosomes, serous miRNAs and exosomal miRNAs had stronger power in predicting HCC than AFP (area under the curve of ROC, 0.943 vs 0.826).
Conclusion
To conclude, the combination of circulating miRNAs and exosomes might serve as promising biomarkers for non-virus infected HCC screening and cirrhosis discrimination.
Similar content being viewed by others
Abbreviations
- HCC:
-
Hepatocellular carcinoma
- AFP:
-
Alpha-fetoprotein
- miRNA:
-
microRNA
- HCSCs:
-
Hepatic cancer stem cells
- HNSCs:
-
Hepatic normal stem cells
- DEN:
-
Diethylnitrosamine
- HAI:
-
Histologic activity index
- ROC:
-
Receiver operating characteristic curve
- AUC:
-
Area under ROC
- EMT:
-
Epithelial-to-mesenchymal transition
References
Bao L, Yan Y, Xu C, Ji W, Shen S, Xu G, Zeng Y, Sun B, Qian H, Chen L, Wu M, Su C, Chen J (2013) MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through AKT/ERK pathways. Cancer Lett 337:226–236
Clevers H (2011) The cancer stem cell: premises, promises and challenges. Nat Med 17:313–319
El-Serag HB (2011) Hepatocellular carcinoma. N Engl J Med 365:1118–1127
Filipe V, Hawe A, Jiskoot W (2010) Critical evaluation of Nanoparticle Tracking Analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates. Pharm Res 27:796–810
Forner A, Llovet JM, Bruix J (2012) Hepatocellular carcinoma. Lancet 379:1245–1255
Giordano S, Columbano A (2013) MicroRNAs: New tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma? Hepatology 57:840–847
Gramantieri L, Fornari F, Callegari E, Sabbioni S, Lanza G, Croce CM, Bolondi L, Negrini M (2008) MicroRNA involvement in hepatocellular carcinoma. J Cell Mol Med 12:2189–2204
Huang YS, Dai Y, Yu XF, Bao SY, Yin YB, Tang M, Hu CX (2008) Microarray analysis of microRNA expression in hepatocellular carcinoma and non-tumorous tissues without viral hepatitis. J Gastroenterol Hepatol 23:87–94
Hubscher SG (1998) Histological grading and staging in chronic hepatitis: clinical applications and problems. J Hepatol 29:1015–1022
Hung CS, Liu HH, Liu JJ, Yeh CT, Chang TC, Wu CH, Ho YS, Wei PL, Chang YJ (2013) MicroRNA-200a and -200b mediated hepatocellular carcinoma cell migration through the epithelial to mesenchymal transition markers. Ann Surg Oncol 20(Suppl 3):S360–S368
Kaneda K, Uenishi T, Takemura S, Yamamoto T, Sakata C, Sakae M, Urata Y, Ohata K, Tanaka S, Wakasa K, Kubo S (2013) Histologically proven hepatocellular carcinoma associated with burned-out nonalcoholic steatohepatitis. Osaka City Med J 59:99–104
Kanwar SS, Dunlay CJ, Simeone DM, Nagrath S (2014) Microfluidic device (ExoChip) for on-chip isolation, quantification and characterization of circulating exosomes. Lab Chip 14:1891–1900
Kitai S, Kudo M, Minami Y, Haji S, Osaki Y, Oka H, Seki T, Kasugai H, Sasaki Y, Matsunaga T (2008) Validation of a new prognostic staging system for hepatocellular carcinoma: a comparison of the biomarker-combined Japan Integrated Staging Score, the conventional Japan Integrated Staging Score and the BALAD Score. Oncology 75(Suppl 1):83–90
Ladeiro Y, Couchy G, Balabaud C, Bioulac-Sage P, Pelletier L, Rebouissou S, Zucman-Rossi J (2008) MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 47:1955–1963
Lan SH, Wu SY, Zuchini R, Lin XZ, Su IJ, Tsai TF, Lin YJ, Wu CT, Liu HS (2014) Autophagy suppresses tumorigenesis of hepatitis B virus-associated hepatocellular carcinoma through degradation of microRNA-224. Hepatology 59:505–517
Leung TW, Tang AM, Zee B, Lau WY, Lai PB, Leung KL, Lau JT, Yu SC, Johnson PJ (2002) Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 94:1760–1769
Li QJ, Zhou L, Yang F, Wang GX, Zheng H, Wang DS, He Y, Dou KF (2012) MicroRNA-10b promotes migration and invasion through CADM1 in human hepatocellular carcinoma cells. Tumour Biol J Int Soc Oncodevelopmental Biol Med 33:1455–1465
Liang HH, Wei PL, Hung CS, Wu CT, Wang W, Huang MT, Chang YJ (2013) MicroRNA-200a/b influenced the therapeutic effects of curcumin in hepatocellular carcinoma (HCC) cells. Tumour Biol J Int Soc Oncodevelopmental Biol Med 34:3209–3218
Liu C, Yu J, Yu S, Lavker RM, Cai L, Liu W, Yang K, He X, Chen S (2010) MicroRNA-21 acts as an oncomir through multiple targets in human hepatocellular carcinoma. J Hepatol 53:98–107
Liu WH, Tao KS, You N, Liu ZC, Zhang HT, Dou KF (2011) Differences in the properties and mirna expression profiles between side populations from hepatic cancer cells and normal liver cells. PLoS One 6:e23311
Liu WH, You N, Zhang N, Yan HT, Wang T, Huang Z, Liu HB, Tang LJ (2012) Interpretation of interlocking key issues of cancer stem cells in malignant solid tumors. Cell Oncol 35:397–409
Llovet JM, Bru C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19:329–338
Magistri P, Leonard SY, Tang CM, Chan JC, Lee TE, Sicklick JK (2014) The glypican 3 hepatocellular carcinoma marker regulates human hepatic stellate cells via Hedgehog signaling. J Surg Res 187:377–385
Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T, Shimotohno K (2006) Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 25:2537–2545
Petrelli A, Perra A, Schernhuber K, Cargnelutti M, Salvi A, Migliore C, Ghiso E, Benetti A, Barlati S, Ledda-Columbano GM, Portolani N, De Petro G, Columbano A, Giordano S (2012) Sequential analysis of multistage hepatocarcinogenesis reveals that miR-100 and PLK1 dysregulation is an early event maintained along tumor progression. Oncogene 31:4517–4526
Petrelli A, Perra A, Cora D, Sulas P, Menegon S, Manca C, Migliore C, Kowalik MA, Ledda-Columbano GM, Giordano S, Columbano A (2014) MicroRNA/gene profiling unveils early molecular changes and nuclear factor erythroid related factor 2 (NRF2) activation in a rat model recapitulating human hepatocellular carcinoma (HCC). Hepatology 59:228–241
Png KJ, Halberg N, Yoshida M, Tavazoie SF (2012) A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. Nature 481:190–194
Ray K (2013) Liver cancer: The promise of new approaches in the management of hepatocellular carcinoma—adding to the toolbox? Nat Rev Gastroenterol Hepatol 10:195
Rekker K, Saare M, Roost AM, Kubo AL, Zarovni N, Chiesi A, Salumets A, Peters M (2014) Comparison of serum exosome isolation methods for microRNA profiling. Clin Biochem 47:135–138
Salnikov AV, Kusumawidjaja G, Rausch V, Bruns H, Gross W, Khamidjanov A, Ryschich E, Gebhard MM, Moldenhauer G, Buchler MW, Schemmer P, Herr I (2009) Cancer stem cell marker expression in hepatocellular carcinoma and liver metastases is not sufficient as single prognostic parameter. Cancer Lett 275:185–193
Szabo G, Bala S (2013) MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol 10:542–552
Tomimaru Y, Eguchi H, Nagano H, Wada H, Kobayashi S, Marubashi S, Tanemura M, Tomokuni A, Takemasa I, Umeshita K, Kanto T, Doki Y, Mori M (2012) Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol 56:167–175
Wang T, You N, Tao K, Wang X, Zhao G, Xia N, Li N, Tang L, Liu W, Dou K (2012) Notch is the key factor in the process of fetal liver stem/progenitor cells differentiation into hepatocytes. Dev Growth Differ 54:605–617
Wang T, Chen T, Liang HY, Yan HT, Lin N, Liu LY, Luo H, Huang Z, Li NL, Liu WH, Tang LJ (2014) Notch inhibition promotes fetal liver stem/progenitor cells differentiation into hepatocytes via the inhibition of HNF-1beta. Cell Tissue Res 357:173–184
Wei L, Lian B, Zhang Y, Li W, Gu J, He X, Xie L (2014) Application of microRNA and mRNA expression profiling on prognostic biomarker discovery for hepatocellular carcinoma. BMC Genom 15(Suppl 1):S13
Wicha MS, Liu S, Dontu G (2006) Cancer stem cells: an old idea—a paradigm shift. Cancer Res 66:1883–1890; discussion 1895–1886
Witwer KW (2015) Circulating MicroRNA biomarker studies: pitfalls and potential solutions. Clin Chem 61:56–63
Xu T, Zhu Y, Wei QK, Yuan Y, Zhou F, Ge YY, Yang JR, Su H, Zhuang SM (2008) A functional polymorphism in the miR-146a gene is associated with the risk for hepatocellular carcinoma. Carcinogenesis 29:2126–2131
Xu G, Zhang Y, Wei J, Jia W, Ge Z, Zhang Z, Liu X (2013) MicroRNA-21 promotes hepatocellular carcinoma HepG2 cell proliferation through repression of mitogen-activated protein kinase-kinase 3. BMC Cancer 13:469
Yeh TS, Wang F, Chen TC, Yeh CN, Yu MC, Jan YY, Chen MF (2014) Expression profile of microRNA-200 family in hepatocellular carcinoma with bile duct tumor thrombus. Ann Surg 259:346–354
Yuan JH, Yang F, Chen BF, Lu Z, Huo XS, Zhou WP, Wang F, Sun SH (2011) The histone deacetylase 4/SP1/microrna-200a regulatory network contributes to aberrant histone acetylation in hepatocellular carcinoma. Hepatology 54:2025–2035
Acknowledgments
National Natural Science Foundation of China (No. 81302168).
Conflict of interest
The authors indicate no potential conflicts of interest.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Wei-hui Liu, Li-na Ren, Xing Wang, Tao Wang, Ning Zhang, Yuan Gao and Hao Luo have contributed equally to this work.
Electronic supplementary material
Below is the link to the electronic supplementary material.
432_2015_1943_MOESM1_ESM.tif
Supplementary figure 1. The expression of miRNAs in tissue samples at different time points after DEN treatment. By in situ hybridization, it was found that the expression of two miRNAs (miRNA-10b and miRNA-21) was gradually increased from 2 weeks to 22 weeks after DEN treatment, while other two tested miRNAs (miRNA-122 and miRNA-200a) were less and less expressed as HCC progressing after chemical induction. Original magnification, 100 ×
432_2015_1943_MOESM2_ESM.tif
Supplementary figure 2. The relative profiles of miRNAs in blood samples at different time points during HCC development. (A) Normalized by the internal reference miRNA-484, relative expression levels of four miRNAs in sera were consecutively either upregulated or downregulated as time went by. (B) The relative folds of miRNA expression in isolated exosomes were reflected in a turning curve chart. DT = during treatment of DEN; AT = after treatment of DEN
432_2015_1943_MOESM3_ESM.tif
Supplementary figure 3. Correlation analysis of serous miRNAs with exosomal miRNAs, and serous miRNAs with miRNAs in liver tissues. (A) The expression of exosomal miRNAs was closely related to that of serous miRNAs. (B) However, the relative expression folds of miRNAs in tissues were moderately correlated with those of the corresponding serous miRNAs
Rights and permissions
About this article
Cite this article
Liu, Wh., Ren, Ln., Wang, X. et al. Combination of exosomes and circulating microRNAs may serve as a promising tumor marker complementary to alpha-fetoprotein for early-stage hepatocellular carcinoma diagnosis in rats. J Cancer Res Clin Oncol 141, 1767–1778 (2015). https://doi.org/10.1007/s00432-015-1943-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-015-1943-0